Overview
Status
Active
Registry date
2018-04-26
Share capital
5,000.00 PLN
Registered address
ul. Towarowa 28, 00-839 Warszawa, Poland
Electronic delivery address
AE:PL-38440-30603-HBBJD-36
Financials
Revenue history (in k)
Filing timeliness
2 of 6 financial statements were filed late (the longest delay 110 days for 2019).
- 202517/12/2025
- 202426/02/2025
- 202322/12/2023
- 202213/01/2023
- 202110/01/2022
- 201902/02/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Division · Manufacture of basic pharmaceutical products and pharmaceutical preparations148 / 231
Top 64%
Results vs industry
Revenue
This companyUSD 285.82kMedianUSD 919.05kAverageUSD 25.83m
Net profit
This companyUSD -114.06kMedianUSD 14.92kAverageUSD 2.77m
Operating costs
This companyUSD 399.77kMedianUSD 873.06kAverageUSD 21.43m
Assets
This companyUSD 141.54kMedianUSD 897.46kAverageUSD 31.52m
Industry
Authorized Representatives
Volker Wiederrich – Management Board Member
Manner of representation
Each member of the management board has the right to represent the company independently
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Odi Pharma Schweiz Ag | 100 | $1,350.62 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2018-05-18.
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Anpharm Przedsiębiorstwo FarmaceutyczneS.A. | $111,469,394.21 | anpharm.pl | ||
| Tarchomińskie Zakłady Farmaceutyczne PolfaS.A. | $102,988,448.02 | polfa-tarchomin.com.pl | ||
| VercoS.A. | $43,577,172.02 | verco.com.pl | ||
| MedicofarmaS.A. | $8,530,473.72 | medicofarma.pl | ||
| VitamaS.A. | $4,287,087.38 | vitama.pl | ||
| Munar PharmaS.A. | $85,649.72 | munar.pl | ||
| Sanford Biotechsp. z o.o. | $2,586.64 | sanfordbiotech.com | ||
| Cefeasp. z o.o. | $294.66 | cefea.pl | ||
| Auxilius PharmaS.A. | $0.83 | auxiliuspharma.com | ||
| Stg25Branch (foreign co.) | – | glagolica.eu |
Change history
| Date | Event | |
|---|---|---|
| 2019-09-16 | Address change (Aleje Jerozolimskie 56c, 00-803, Warszawa → Ul. Towarowa 28, 00-839, Warszawa) | |
| 2018-11-17 | Name change (Di Pharma Polska → Odi Pharma Polska) | |
| 2018-10-12 | Name change (Balansat Investments → Di Pharma Polska) | |
| 2018-10-12 | PKD change (Removed: 10 codes; Added: 10 codes) | |
| 2018-04-26 | Entered in the register |
FAQ
The main business activity of ODI Pharma Polska focuses on manufacture of pharmaceutical preparations.
The company was registered in the Polish National Court Register (KRS) on April 26, 2018.
The headquarters is located at: ul. Towarowa 28, 00-839 Warszawa.
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from July 1, 2024 to June 30, 2025.
The company reported a revenue of $285,825 in 2025, which is a decrease of 86.4% compared to 2024.
No, in 2025 the company was not profitable, reporting a net loss of $114,064.
The largest operating cost category falls under other operating costs. This category amounted to $399,773 in 2025, representing 100% of all operating expenses.
Last updated: 2026-10-07
